Read the Latest News

A Tribute to William “Bill” Maixner, Ph.D., D.D.S

All of us at The TMJ Association are deeply saddened by the loss of a treasured friend, an accomplished and highly respected scientist, empathic clinician and one of temporomandibular disorder's (TMJ) greatest champions – Dr. William “Bill” Maixner. Bill passed away on Monday, November 2, 2020, at the age of 68.

New Report on Temporomandibular Disorders: Priorities for Research and Care

Over a year and half ago, the National Academy of Medicine (NAM) began the most comprehensive study ever undertaken on Temporomandibular Disorders (TMD). The study assessed the current state of TMD research, education and training, the safety and efficacy of clinical treatments, and associated burden and costs.

Statement by NIDCR Acting Director on the National Academies of Sciences, Engineering, and Medicine Report on Temporomandibular Joint Disorders

I am pleased to announce the release of the National Academies of Sciences, Engineering, and Medicine (NASEM) report, Temporomandibular Disorders: Priorities for Research and Care. As underscored by the comprehensive report, temporomandibular joint disorders (TMJDs) are a diverse and still poorly understood set of complex, painful conditions affecting the jaw muscles and tissues, temporomandibular joints, and associated nerves. Clearly, there is much more to be understood, and these conditions continue to confound medical and dental health care providers and researchers.

Have you seen the film Dark Waters?

The Film. Dark Waters is about attorney Robert Billott's real-life 20 year legal battle against DuPont chemical for releasing toxic waste - perfluorooctanoic acid, or PFOA - into Parkersburg, West Virginia's water supply, with devastating health effects on the townspeople and livestock. PFOA, also known as C8, is a man-made chemical. It is used in the process of making Teflon and similar chemicals known as fluorotelomers.

Online TMD Diet Diary Research Project

Online TMD Diet Diary Research Project The TMJ Association received the following request from Professor Justin Durham and his research team at Newcastle University. We encourage TMJ patients to participate in this project as it is an under researched

NIH GRANT OPPORTUNITIES

  • Jun 29, 2020

In an effort to promote greater understanding of Temporomandibular Disorders (TMD) and to develop safe and effective evidence-based diagnostics and treatments, . The TMJ Association promotes and encourages basic and clinical research on TMD.  We invite you to view a listing of the latest National Institutes of Health (NIH) funding opportunities for scientists interested in advancing TMJ research.

 

Notice of Special Interest of NIDCR in Supporting Discovery, Characterization, and Mechanistic Study of Genetic Variants Underlying Dental, Oral, and Craniofacial Diseases and Conditions

https://grants.nih.gov/grants/guide/notice-files/NOT-DE-19-016.html?utm_medium=email&utm_source=govdelivery

  • Posted Date: October 29, 2019
  • Open Date: January 7, 2020
  • Expires: January 8, 2022

While considerable progress has been made in associating genetic variants with common and rare DOC diseases and conditions, knowledge is not yet complete about genes involved and genetic variation, heterogeneity, penetrance, and expressivity. In addition, functional characterization and mechanistic studies of DOC genes and variants have not yet been carried out fully to gain a better understanding of DOC biology and disease etiology.

Specific Areas of Research Interest

This Notice calls for research projects targeting human DOC phenotypes that propose specific aims in each of the following categories: 1) discovery of candidate causal genetic variants, 2) functional characterization of identified variants, and 3) mechanistic studies.

  1. Applicants should propose genome-wide (whole exome, whole genome, or transcriptome) sequencing and analysis of human study participants, aiming for discovery of novel DOC variants or novel phenotypes previously not associated with any known DOC variant, with or without complementary ‘omics approaches including genotyping.
  2. Applicants should propose characterization of functional significance/consequences of identified human candidate genes/variants using animal models, in vitro systems, in silico methods, or other approaches.
  3. Concurrent with functional characterization, or under a separate aim, applicants should propose experimental and/or analytical work that can shed light on mechanistic aspects of disease etiology.

Work proposed must be well-justified with strong scientific rational and consideration of costs. For example, whole genome sequencing and analysis, rather than whole exome sequencing and analysis, as the main or sole approach for discovery of candidate causal variants, must be well-justified.

While an applicant can request funds for all proposed aims, he/she is highly encouraged to capitalize on existing resources for the proposed project to reduce costs and integrate all necessary expertise. Examples include, but are not limited to:

  1. A project that analyzes existing sequencing and phenotypic data for the variant discovery aim, while requesting funds for follow-up phenotyping and sequencing of a subset of study participants.
  2. A project that sequences and analyzes existing and well-phenotyped study participants for the variant discovery aim. If necessary, the project can request funds for additional and well-designed recruitment and/or phenotyping of existing and/or new participants.
  3. A project that teams up with a research group that seeks research collaboration and offers sequence production and analysis at no cost to the new project.
  4. A project that collaborates with an existing program for functional characterization of candidate causal variants.

The Intersection of Sex and Gender Influences on Health and Disease (R01)

https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-19-029.html

  • Posted Date: September 27, 2019
  • Open Date: October 25, 2019
  • Expires: November 27, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications on the influence and intersection of sex and gender in health and disease including:  (1) research applications that examine sex and gender factors and their intersection in understanding health and disease; and (2) research that addresses one of the five objectives from Strategic Goal 1 of the new 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women." The awards under this FOA will be administered by NIH ICs using funds that have been made available through the Office of Research on Women’s Health (ORWH) and the scientific partnering Institutes and Centers across NIH.

Achieving Tissue Robustness Through Harnessing Immune Systems Plasticity

(R21 Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/pa-files/PAR-19-173.html

(R01) Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/pa-files/PAR-19-172.html

  • Posted Date: January 29, 2019
  • Open Date: May 16, 2019
  • Expires: May 8, 2022

This funding opportunity announcement (FOA) encourages state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial (DOC) diseases. This FOA encourages applications that will seek to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward regeneration disease management in a patient-specific manner across the lifespan.

Recent advances in understanding diseases and conditions involving DOC tissues – periodontitis, peri-implantitis, temporomandibular joint disorders (TMD), oral and oropharyngeal cancers, Sjögren’s Syndrome, and HIV/AIDS with its associated oral opportunistic infections, among others - demonstrate that the immune system significantly contributes to disease onset, progression, and persistence.

HEAL Initiative Funding Opportunities

HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/rfa-files/rfa-eb-18-003.html

The purpose of this Funding Opportunity Announcement (FOA) is to support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress.

Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/rfa-files/rfa-ns-19-016.html

The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and clinical trials to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical trial (e.g., Early Feasibility Study). The clinical trial is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress.

HEAL Initiative: Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional) https://grants.nih.gov/grants/guide/rfa-files/rfa-ns-19-017.html

The purpose of this Funding Opportunity Announcement (FOA) is to encourage small business concerns (SBCs) to pursue translational activities and clinical trials to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical trial (e.g., Early Feasibility Study). The clinical trial is expected to provide information about the device function or final design that cannot be practically obtained through additional nonclinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress.

HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional) https://grants.nih.gov/grants/guide/rfa-files/rfa-ns-19-018.html

The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat pain with innovative, targeted, and non-addictive diagnostic and/or therapeutic devices that improve patient outcomes and decrease or eliminate the need to prescribe opioids. Clinical studies supported may consist of acute or short-term procedures that are deemed Non-Significant Risk (NSR) by an Institutional Review Board (IRB), or Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants.  The clinical trial should provide data to answer key questions about the function or final design of a device and is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress.

HEAL Initiative: Stimulating Peripheral Activity to Relieve Conditions (SPARC): Anatomical and Functional Mapping of Pain-Related Visceral Organ Neural Circuitry (U01 Clinical Trial Optional) https://grants.nih.gov/grants/guide/rfa-files/rfa-rm-19-001.html

The purpose of this NIH Funding Opportunity Announcement (FOA) is to invite research applications proposing to map neural circuitry mediating visceral organ pain. This FOA is part of the Stimulating Peripheral Activity to Relieve Conditions (SPARC) Common Fund program and is coordinated with the Translational Devices to Treat Pain (TDTP) initiatives of the NIH HEAL program (see Companion Funding Opportunities above). Detailed mapping of pain-mediating circuitry originating from visceral organ afferents will leverage the SPARC program to produce maps that could accelerate the development of non-addictive approaches to treat pain.

Additional information about the HEAL Initiative can be found at: NIH Director’s Statement regarding new HEAL FOAs and Updated NIH HEAL Research Plan

  • Posted Date: December 10, 2018
  • Open Date: varies see specific funding opportunity
  • Expires: February 23, 2021

Global Brain and Nervous System Disorders Research Across the Lifespan

  • Posted Date: June 19, 2018
  • Open Date: October 7, 2018
  • Expires: October 7, 2020
The mission of the National Institute of Dental and Craniofacial Research (NIDCR) is to improve dental, oral, and craniofacial health through research, research training, and the dissemination of health information; for further details, please see the NIDCR Strategic Plan 2014-2019 (https://www.nidcr.nih.gov/research/ResearchPriorities/StrategicPlan/). Through this FOA, NIDCR encourages research in orofacial pain, trigeminal neuralgia, temporomandibular joint disorder, and oral cancer pain.

 

Research on Chronic Overlapping Pain Conditions

  • Posted Date: September 26, 2018
  • Open Date: January 16, 2019
  • Expires: January 8, 2022

The purpose of this FOA is to encourage epidemiological, clinical and translational research that will increase our understanding of the presence of multiple chronic pain conditions in subjects with pain. Recent findings suggest substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, their underlying etiologies, the evolution of these overlaps, and the therapeutic approaches best suited for treating subjects with these conditions. The main objective of this FOA is the formation of research groups with research interests bridging expertise in pain mechanisms and translational and clinical expertise to address important unresolved questions about overlapping pain conditions.

Chronic pain affects approximately 100 million Americans and exacts large economic, social and personal costs. It is a major public health challenge that needs to be addressed at multiple levels including the generation of new scientific knowledge that will enhance our understanding of these conditions. Current research efforts in chronic pain conditions have focused on single disorders or types of pain such as neuropathic and inflammatory pain. These research efforts have generated a substantial body of information advancing our discovery and understanding of the underlying mechanisms of pain onset and development, the transition from acute to chronic pain, and promising therapeutic targets for treating acute and chronic pain. Over the past twenty years sporadic reports have documented the presence of more than one chronic pain condition in subjects with pain. Studies have identified overlap between a number of chronic pain conditions, including temporomandibular joint disorder (TMD), fibromyalgia (FM), vulvodynia, functional gastrointestinal disorders such as irritable bowel syndrome (IBS), migraine, and urologic chronic pelvic pain syndromes (UCPPS). These results suggest that chronic pain conditions may not be localized conditions, but may share symptoms and mechanisms that involve a general central nervous system dysfunction as well as disorder-specific symptoms. More recent evidence is supportive of the idea that chronic pain conditions are complex disorders consistent with a biopsychosocial model of pain, and exhibit substantial overlap. Therefore, this may be an opportune time to encourage research efforts that focus, not on single pain conditions, but on subjects with multiple chronic pain disorders.

 

Clinical Validation of Candidate Biomarkers for Neurological Diseases

  • Posted Date: February 14, 2018
  • Open Date: March 17, 2018
  • Expires: February, 14, 2019; July 18, 2019; February 14, 2020; and July 20, 2020
The purpose of this Funding Opportunity Announcement (FOA) is to support rigorous clinical validation of a candidate biomarker using retrospective and/or prospective methods in a manner that is consistent with the purpose of the biomarker. This FOA assumes that: 1) a candidate biomarker has already been identified, 2) an analytical method has been developed and validated that is consistent with the purpose of the biomarker and 3) a working hypothesis regarding context of use is in place. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers of diseases that fall within the mission of NINDS to application in clinical trials and practice (Phase II clinical trials and beyond).
 

 

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize well-validated hit compounds through medicinal chemistry, or at the Development stage, to advance development candidates through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN participants receive intellectual property rights to drug candidates developed through the program.     - See more at: http://grants.nih.gov/grants/guide/pa-files/PAR-14-293.html#sthash.mGoDkIgW.dpuf

The purpose of this Funding Opportunity Announcement (FOA)is to encourage research into dental, oral, and craniofacial diseases and disorders for which there is evidence for genetic heritability but for which we do not have a strong understanding of the genetics/genomics of the disease or disorder. Applicable areas of investigation include identification of promising areas of the genome, and characterization and elucidation of the function(s) of genetic variants that affect disease risk in humans. The ultimate goal of these studies will be to drive development of effective diagnostic, therapeutic, and preventive approaches. - See more at: http://grants.nih.gov/grants/guide/pa-files/PA-14-347.html#sthash.viviyVB9.dpuf

Family-Centered Self-Management of Chronic Conditions

(R21): https://grants.nih.gov/grants/guide/pa-files/PA-18-380.html

(R01):https://grants.nih.gov/grants/guide/pa-files/PA-18-383.html

  • Posted Date: November 21, 2017
  • Open Date: January 16, 2018 / January 5, 2018
  • Expires: January 8, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of family-centered self-management (FCSM) in chronic conditions.

mHealth Tools for Individuals with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self-Management

(R01): https://grants.nih.gov/grants/guide/pa-files/PA-18-386.html

(R21): https://grants.nih.gov/grants/guide/pa-files/PA-18-389.html

  • Posted Date: November 21, 2017
  • Open Date: January 5, 2018
  • Expires: January 8, 2021

The purpose of this initiative is to stimulate research utilizing Mobile Health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases. With the rapid expansion of cellular networks and substantial advancements in Smartphone technologies, it is now possible - and affordable - to transmit patient data digitally from remote areas to specialists in urban areas, receive real-time feedback, and capture that consultation in a database. These mHealth tools, therefore, may facilitate more timely and effective patient-provider communication through education communication around goal setting, treatment reminders, feedback on patient progress, and may improve health outcomes. This announcement encourages the development and testing of interventions utilizing mHealth technologies. There is also an interest in studying mHealth technologies in underserved populations. 

The Biomarkers Consortium

The Biomarkers Consortium, a research partnership managed by the Foundation for the National Institutes of Health, is soliciting concepts for biomarker projects. Researchers are encouraged to submit project concepts online at http://www.biomarkersconsortium.org. If a concept is approved for development by the consortium, the Foundation for NIH will seek funds to support the project.

The consortium is a large-scale, public-private research partnership formed in 2006 to identify and qualify biomarkers. It encourages participation by academia, government, industry, patient advocacy groups and other non-profit organizations. In addition to the Foundation for NIH, founding members of the consortium include the NIH, the Food and Drug Administration and the Pharmaceutical Research and Manufacturers of America.

Information about the Foundation for NIH is available at http://www.fnih.org.

 

Mechanisms Underlying the Contribution of Sleep Disturbances to Pain

(R01 Clinical Trial Optional) https://grants.nih.gov/grants/guide/pa-files/PA-19-200.html?utm_medium=email&utm_source=govdelivery

(R21 Clinical Trial Optional) https://grants.nih.gov/grants/guide/pa-files/PA-19-201.html?utm_medium=email&utm_source=govdelivery

  • Posted Date: February 28, 2019
  • Open Date: May 16, 2019
  • Expires: May 8, 2022

The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fields—neuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry. Applications proposing to study the impact of pain on sleep will be considered low priority and are unlikely to be funded under this FOA.

This Notice encourages investigators with expertise and insights into the broad area of Medical Rehabilitation Research sufficient time to develop applications in response to this new FOA. NICHD encourages collaborations among biomedical, behavioral, engineering, and/or psychosocial researchers. Aside from more traditional rehabilitation approaches, NICHD especially encourages support for clinical trial design, applied behavior, engineering and the environment, and personalized medicine in order to promote functional improvement, rehabilitation, and participation for people with disabilities. - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-HD-14-022.html#sthash.GsPMcpHa.dpuf
This Notice encourages investigators with expertise and insights into the broad area of Medical Rehabilitation Research sufficient time to develop applications in response to this new FOA. NICHD encourages collaborations among biomedical, behavioral, engineering, and/or psychosocial researchers. Aside from more traditional rehabilitation approaches, NICHD especially encourages support for clinical trial design, applied behavior, engineering and the environment, and personalized medicine in order to promote functional improvement, rehabilitation, and participation for people with disabilities. - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-HD-14-022.html#sthash.GsPMcpHa.dpuf
This Notice encourages investigators with expertise and insights into the broad area of Medical Rehabilitation Research sufficient time to develop applications in response to this new FOA. NICHD encourages collaborations among biomedical, behavioral, engineering, and/or psychosocial researchers. Aside from more traditional rehabilitation approaches, NICHD especially encourages support for clinical trial design, applied behavior, engineering and the environment, and personalized medicine in order to promote functional improvement, rehabilitation, and participation for people with disabilities. - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-HD-14-022.html#sthash.GsPMcpHa.dpuf